Abstract: A communication gateway for connecting an LPWAN network to a network for access to a cellular or RAN network, the LPWAN network and the RAN network using radio links. Such a gateway typically allows connected objects and servers on the Internet to communicate according to the Internet of Things (IoT) architecture. However, the proximity of the frequency bands used for the two radio links may lead to mutual interference between them, the transmitter of one interfering with the receiver of the other, especially when the gateway is miniature, of the order of magnitude of the connected objects (approximately 10 cm). The disclosed gateway electromagnetically isolates the two RF channels by means of double filtering: by a bandpass filter on the LPWAN RF channel combined with a rejection filter on the cellular RF channel.

Abstract: The present document describes a pharmaceutical composition comprising a) a lipid nanoparticle operable to encapsulate a therapeutic agent, comprising a core and an external surface, said therapeutic agent being encapsulated within said core; said lipid nanoparticle having a size of said lipid nanoparticle of from about 30 to about 80 nm, or a pegylated lipid comprising a distearoyl-rac-glycerol (DSG)-PEG and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(DSPE)-PEG-DBCO; or a combination of: a size of from about 30 to about 80 nm and a pegylated lipid comprising a DSG-PEG and DSPE-PEG-DBCO; and b) an antibody or antigen-binding fragment thereof operable to transmigrate the blood-brain barrier (BBB), wherein the antibody or antigen-binding fragment thereof comprises complementarity determining regions (CDR1, CDR2 and CDR3), operably linked to said external surface of said lipid nanoparticle.

Abstract: The present document describes antibodies or antigen-binding fragments that bind specifically to a target antigen, wherein the antibodies or antigen-binding fragments comprise complementarity determining regions (CDR1, CDR2 and CDR3) and an added O-glycosylation sequon glycosylated with an O-glycan having the general formula (I): wherein R1 is an initial N-acetylgalactosamine (GalNAc); n=1, or 2; R2 are each independently absent, galactose (Gal), GalNAc, N-Acetylglucosamine (GlcNAc), or a sialic acid; R3 are each independently absent, Gal or a sialic acid; and R4 are each independently absent or a sialic acid. Also described are compounds comprising the antibodies or antigen-binding fragments comprising a functional moiety operably linked to said O-glycan, compositions comprising the same, and methods of preparing such compounds.

Abstract: A communication gateway for connecting an LPWAN network to a network for access to a cellular or RAN network, the LPWAN network and the RAN network using radio links. Such a gateway typically allows connected objects and servers on the Internet to communicate according to the Internet of Things (IoT) architecture. However, the proximity of the frequency bands used for the two radio links may lead to mutual interference between them, the transmitter of one interfering with the receiver of the other, especially when the gateway is miniature, of the order of magnitude of the connected objects (approximately 10 cm). The disclosed gateway electromagnetically isolates the two RF channels by means of double filtering: by a bandpass filter on the LPWAN RF channel combined with a rejection filter on the cellular RF channel.

Abstract: The present invention relates to compounds, compositions, and methods are provided for covalently linking a cargo molecule, such as a therapeutic or a diagnostic agent, to a glycan in the Fab region of an antibody. Also provided are methods of modeling and producing antibodies having de novo Fab glycosylation sites. Also provided are antibody carrier conjugates, methods of using the conjugates.

Abstract: The present invention relates to compounds, compositions, and methods are provided for covalently linking a cargo molecule, such as a therapeutic or a diagnostic agent, to a glycan in the Fab region of an antibody. Also provided are methods of modeling and producing antibodies having de novo Fab glycosylation sites. Also provided are antibody carrier conjugates, methods of using the conjugates.

Abstract: A gateway architecture able to meet the challenges raised by the large-scale deployment of wireless sensor networks. The main modules within such a gateway for wireless sensor networks, for example digital radio modems and analog radio interface modules take the form of various separate physical blocks that may be joined together. This technique makes it possible to implement adaptable and scalable modular gateways that may be quickly and easily configured or suited to any situation, simply by replacing existing physical blocks or adding new physical blocks.

Abstract: A gateway architecture able to meet the challenges raised by the large-scale deployment of wireless sensor networks. The main modules within such a gateway for wireless sensor networks, for example digital radio modems and analog radio interface modules take the form of various separate physical blocks that may be joined together. This technique makes it possible to implement adaptable and scalable modular gateways that may be quickly and easily configured or suited to any situation, simply by replacing existing physical blocks or adding new physical blocks.

Abstract: The invention relates to sialate-O-acetyltransferase (SOAT) polypeptides, nucleic acids that encode the polypeptides, and methods of using the polypeptides.

Abstract: ?-1,4-galactosyltransferase (CgtD) polypeptides, nucleic acids that encode the polypeptides, including a polypeptide from Campylobacter jejuni strain LIO87 have been isolated and characterized. A method of producing a galactosylated saccharide comprising contacting an acceptor saccharide containing a terminal galactose, a donor substrate comprising a galactose moiety and one of the CgtD polypeptides is described.

Abstract: The invention relates to poly-sialyltransferse polypeptides with enhanced solubility and activity and methods of using the poly-sialyltransferases for production of poly-sialylated end products, e.g., oligosaccharides, glycoproteins and glycolipids.

Abstract: CgtB proteins with enhanced beta 1,3-galactosaminyltransferase activity, nucleic acids that encode the CgtB proteins and methods for use of the CgtB proteins.

Abstract: The invention relates to ?-1,3-N-acetylgalactosaminyltransferase polypeptides, nucleic acids that encode the polypeptides, and methods of using the polypeptides.

Abstract: The invention relates to a fusion protein comprising a bifunctional sialytransferase and a poly-sialytransferase and methods to use the fusion proteins for production of poly-sialylated end products, e.g. oligosaccharides and glycoproteins.

Abstract: CgtB proteins with enhanced beta 1,3-galactosaminyltransferase activity, nucleic acids that encode the CgtB proteins and methods for use of the CgtB proteins.

Abstract: The invention relates to poly-sialyltransferse polypeptides with enhanced solubility and activity and methods of using the poly-sialyltransferases for production of poly-sialylated end products, e.g., oligosaccharides, glycoproteins and glycolipids.

Abstract: ?-1,4-galactosyltransferase (CgtD) polypeptides, nucleic acids that encode the polypeptides, including a polypeptide from Campylobacter jejuni strain LIO87 have been isolated and characterized A method of producing a galactosylated saccharide comprising contacting an acceptor saccharide containing a terminal galactose, a donor substrate comprising a galactose moiety and one of the CgtD polypeptides is described.

Abstract: This invention provides prokaryotic glycosyltransferases, including a bifunctional sialyltransferase that has both an ?2,3- and an ?2,8-activity. A ?1,4-GalNAc transferase and a ?1,3-galactosyltransferase are also provided by the invention, as are other glycosyltransferases and enzymes involved in synthesis of lipooligosaccharide (LOS). The glycosyltransferases can be obtained from, for example, Campylobacter species, including C. jejuni. In additional embodiments, the invention provides nucleic acids that encode the glycosyltransferases, as well as expression vectors and host cells for expressing the glycosyltransferases.

Abstract: The invention relates to a fusion protein comprising a bifunctional sialytransferase and a poly-sialytransferase and methods to use the fusion proteins for production of poly-sialylated end products, e.g. oligosaccharides and glycoproteins.

Abstract: The present invention provides, e.g., sialyltransferase proteins comprising conserved sequence motifs, including ?-2,3-sialyltransferase proteins from C. jejuni strains O:36 and O:19. The invention also provides methods of making sialylated products using those sialyltransferases.